Increased premature mortality of competitive powerlifters suspected to have used anabolic agents

International Journal of Sports Medicine

Volumn 21, Issue 3, 2000, Pages 225-227

  Pärssinen, Miia ^a   Kujala, U ^b   Vartiainen, E ^a   Sarna, S ^c   Seppala T ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Anabolic steroids; Cardiovascular diseases; Doping; Increased mortality; Suicides

Indexed keywords

ANABOLIC AGENT;

ADULT; ARTICLE; ATHLETE; CAUSE OF DEATH; DOPING; DRUG MISUSE; HEART INFARCTION; HEPATIC COMA; HUMAN; MALE; MORTALITY; NONHODGKIN LYMPHOMA; SUICIDE;

ADULT; ANABOLIC AGENTS; CAUSE OF DEATH; DOPING IN SPORTS; FINLAND; HUMANS; MALE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS; WEIGHT LIFTING;

EID: 0034101625     PISSN: 01724622     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-304     Document Type: Article

References (19)

1. 1 Alén M. Effects of self-administered, high-dose testosterone and anabolic steroids on serum hormones, lipids, enzymes and on spermatogenesis in power athletes. Jyväskylä: University of Jyväskylä, 1985
2. 2 Bahrke MS, Yesalis CE, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. Sports Med 1996; 22: 367-390
3. 3 Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1-7
4. 4 Corrigan B. Anabolic steroids and the mind. MJA 1996; 165: 222-226
5. 5 DuRant RH, Rickert VI, Ashworth CS, Newman C, Slavens G. Use of multiple drugs among adolescents who use anabolic steroids. N Engl J Med 1993; 328: 922-926
6. 6 Korkia P, Stimson GV. Indications of prevalence, practise and effects of anabolic steroid use in Great Britain. Int J Sports Med 1997; 18: 557-562
7. 7 Kujala UM, Kaprio J, Taimela S, Sarna S. Prevalence of diabetes, hypertension and ischemic heart disease in former elite athletes. Metabolism 1994; 43: 1225-1260
8. 8 Kujala UM, KaprioJ, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality. The Finnish Twin Cohort. JAMA 1998; 279: 440-444
9. 9 Magnavita N, Teofili L, Leone G. Hodgkin's lymphoma in a cyclist treated with growth hormone. Am J Hematol 1996; 52: 65-66
10. 10 Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exec 1995; 27: 1252-1262
11. 11 Middleman AB, Faulkner AH, Woods ER, Emans SJ, DuRant RH. High-risk behaviors among high school students in Massachusetts who use anabolic steroids. Pediatrics 1995; 96: 268-272
12. 12 Morris JN, Everitt MG, Pollard R, Chave SPW. Vigorous exercise in leisure-time: Protection against coronary heart disease. Lancet 1980; 2: 1207-1210
13. 13 Nieminen MS, Rämö MP, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1996; 17: 1576-1583
14. 14 Paffenbarger RS Jr, Hyde RT, Wing AL, Lee I-M, Jung DL, Kambert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538-545
15. 15 Sarna S, Sahi T, Koskenvuo M, Kaprio J. Increased life expectancy of world class male athletes. Med Sci Sports Exec 1993; 25: 237-244
16. 16 Søe KL, Søe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12: 73-79
17. 17 Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994; 309: 23-27
18. 18 Wilson JD. Androgen abuse by athletes. Encocr Rev 1988; 9: 181-199
19. 19 Yesalis CE, Wright JE, Bahrke MS. Epidemiological and policy issues in the measurement of the long term health effects of anabolic-androgenic steroids. Sports Med 1989; 8: 129-138